Hypoglycemic ọgwụ ọjọọ nke ọgbọ ọhụrụ na ha nhazi ọkwa

Ndị na-arịa ọrịa shuga Ụdị nke Abụọ-arịa ọrịa shuga nwere mgbe niile nyochaa larịị nke glucose dị n'ọbara. Ọ bụ naanị mgbe ndị nkịtị kwa pụrụ iduga a kwesịrị ndụ. Mgbe ọbara sugar adahade, dọkịta gị nwere ike nye iwu ka a pụrụ iche nkwadebe maka normalisation nke ọrịa na-arịa. Ọtụtụ n'ime ndị ọgwụ ọjọọ na otu a na-emepụta mbadamba. All ọgwụ (antidiabetic) na-ekewa n'ime sulfonylurea nkwekọrịta, prandial glucose regulators, biguanides, Alfa-glucosidase inhibitors na insulin sensitayzery. na Nchikota pụtara na-hụrụ na pharmacies.

sulfonylureas

Drug ọgwụgwọ malitere ndinọ ka ọrịa na-arịa ọrịa shuga Ụdị nke Abụọ na mmalite 60 nke narị afọ gara aga. Taa sulfonylurea nkwekọrịta bụ ewu ewu nnọọ. Ọgwụ iche mbụ na nke abụọ emana. The mbụ na oge a na-eme na-adịkarịghị eji. Drugs na otu a hypoglycemic kenyere ka ọrịa na a buru ibu arọ, ma ọ bụrụ na e nwere ndị na-abụghị insulin ndabere-arịa ọrịa shuga mellitus. The enweghị akwụ ụgwọ nke carbohydrate metabolism bụ kpọmkwem grandstanding n'ihi nzube nke sulfonylurea emepụta.

Antidiabetic ọgwụ ọjọọ nke ọgbọ ọhụrụ kere na ndabere nke sulfonylureas ike ga-eji dị ka otu nọọrọ onwe ha n'aka ọgwụgwọ. Ọgwụ na-arụkọ ọgwụ. Otú ọ dị, isi ọrụ na-egwuri site nri. Ọ bụrụ na onye ọrịa ga-eri machibidoro iwu oriri mgbe na-ewere ọgwụ, ẹsụhọde ọbara sugar, a eti utịp nwere ike na-atụ anya.

Lezienụ anya! Hypoglycemic mmadụ adịghị kenyere ọrịa na-ata ahụhụ site na insulin na pancreatic arịa ọrịa shuga. Ị gaghị na-etinye ọgwụ si otu a ụmụaka, na ime, lactating inyom.

"Glipizide"

Nkwadebe akọ abụọ emana sulfonylureas. N'aka na-akpali akpali insulin mmepụta si pancreas nke functionally ifịk beta-mkpụrụ ndụ, na-na-achị ego nke glucose na mkpụrụ ndụ nke ọrịa na-agafeghị oke na oké iche nke insulin-ndabere-arịa ọrịa shuga. The agwọ ọrịa a na-eresị na pharmacies n'ụdị mbadamba, onye ọ bụla nwere 0,005 g nke nọ n'ọrụ umi. Nkwadebe "Glipizide" amalite na-eme ihe mgbe 30 nkeji mgbe nlekọta na mgbe awa 24 kpamkpam tutu amama si ahụ.

The onunu ogwu nke ọgwụ na-guzosie ike dibịa n'otu n'otu. Ọ bụla hypoglycemic ọgwụ ọjọọ na-kenyere nanị mgbe a na usoro nke ule. The dibịa guzosie ike, a zuru ezu na-adakarị picture. The mbụ kwa ụbọchị dose ekwesịghị gafere 0,005 g (otu mbadamba). Na ihe ndị kasị oké ikpe onye ọrịa nwere ike iri 2-3 mbadamba na a oge. The kacha kwa ụbọchị dose ekwesịghị gafere 0.045, bụ mbadamba nkume na-e 30 nkeji tupu nri. Na mgbanwe site insulin, ọbara glucose etoju dị mkpa ịchịkwa mbụ ụbọchị ole na ole.

Mmetụta mgbe na-eji ọgwụ ọjọọ, "Glipizide" fọrọ anọghị. Na obere okwu, nwere ike ime adịghị ike, na dizziness. Ndị dị otú ahụ na nsogbu nwere ike mfe tutu amama site agbazi onunu ogwu. Ọtụtụ mgbe mmetụta ime na agadi ọrịa. Antidiabetic ọgwụ ọjọọ nke ọgbọ ọhụrụ iji na rụọ ọrụ ndị ahụ ike nke ndị na-arịa ọrịa shuga. Ọ bụla wetara Jeremaya mere akwụsị n'ime ụbọchị ole na ole mgbe nnabata nke ọgwụ. Contraindication inweta ego "Glipizide" bụ ime na idiosyncrasy sulfonamides. Children ọgwụ a na-adịghị kenyere.

"Gliquidone"

Ọzọ hypoglycemic mmadụ, nke na-akọ na nkwekọrịta nke sulfonylureas. Dị ka na aga n'aka, ọ akpali mmepụta nke insulin na beta sel nke pancreas na mma insulin uche nke elu arọ. Pụtara "gliquidone" e ji a ọma na-adịgide adịgide mmetụta. Na ọtụtụ ọgwụ (hypoglycemic) akpata hyperinsulinemia. Gịnị nwere ike kwuru banyere ọgwụ "gliquidone".

The ọgwụ dị na pharmacies dị ka mbadamba. Kenye ya ọrịa na Type II-arịa ọrịa shuga, na ndị agadi ndị ọrịa na onye na-eri ọgwụ adịghị enye eti utịp. The onunu ogwu kpebisiri ike dabere na onye e ji mara onye ahụ, dị ka nke ọma dị ka ya na-adakarị picture. The kacha nta kwa ụbọchị dose bụ 15 mg, karịa - 120 mg. Mbadamba na-e tupu eri. Na milder iche nke-arịa ọrịa shuga, naanị otu Erere a ụbọchị. iri ọgwụ obere mgbe 2-3 ugboro n'ụbọchị.

Mmetụta si ndibọbọ pụtara "gliquidone" adị, ma, ha na-reversible. Mgbe mbụ ogbo nke ọgwụgwọ nwere ike ime ọrịa pruritus na dizziness. Wetara ihe mgbaàmà na-apụ n'anya na-esote ụbọchị mgbe mmalite nke ọgwụ. Kagbuo ọgwụ naanị na ihe omume nke a na oké anabata. Onye ekweghị ibe nọrọ na-adị infrequently. Hypoglycemic preparations nke usoro isiokwu a na-adịghị kenyere ka ọrịa na a mbụ ụdị ọrịa shuga. N'oge ọgwụgwọ, anyị ga-echefu na obara gi sugar. Ọ bụrụ na ọnụ ọgụgụ ga-elu karịa nkịtị, ị kwesịrị ịkpọ onye dọkịta ndị ga-agbanwe omume Usoro.

Mgbe bụghị prescribers sulfonilmochevny?

Predkomatoznoe ala, na-arịa ọrịa shuga amaghị onwe bụ a oké njọ contraindication na ebe a na-adabere sulfonilmochevny ọgwụgwọ. Adịghị eji onu hypoglycemic mmadụ na usoro isiokwu a nwekwara n'oge ime na lactation, n'agbanyeghị ihe n'ihi a rụzuworo na mbụ.

Kasị dị ize ndụ ụmụ mmadụ ọrịa, na-ata ahụhụ site na Type II-arịa ọrịa shuga, nwere ọ bụla n'ịwa ahụ. Aka ndidi nchekwa agha, nkwekọrịta sulfonilmochevny nwa oge kagbuo. Rube isi ụkpụrụ a na-efe efe. Isi mesiri ike na-emeso ndị ọrịa na nnukwu na-adọ. Ka anya dị ka onye ọrịa na-enwe azụ nkịtị, a ọhụrụ antidiabetic ọgwụ ọjọọ nwere ike na-kenyere. Ọ bụrụ na contraindications na ojiji nke sulfonilmochevny bụghị, i nwere ike na-amalite na-anata ọgwụ ọjọọ na usoro isiokwu a.

Prandial glucose regulators

Ọ na-e-eduzikwa ọtụtụ ọmụmụ nke amino asịd, na N'ezie nke nke e gosipụtara na ọrụ ha na insulin secretion. Ọ hụrụ na analogs benzoevoy acid na phenylalanine nwere hypoglycemic edinam. Prandial glucose regulators nwere ike ịchịkwa secretion nke insulin ozugbo nri. Ma ọ bụ na a na ogbo nke sharply ụba etoju nke ọbara glucose. New hypoglycemic mmadụ nwere a na-adịghị adịte mmetụta. Ntre ha naanị n'oge ma ọ bụ mgbe a nri. Iji ọgwụ ọjọọ eme ihe iji gbochie na-ekwesịghị ekwesị.

N'agbanyeghị eziokwu na ndị nhazi ọkwa nke hypoglycemic mmadụ na-agụnye prandial glucose regulators, ha na-adịghị eji nnọọ mgbe. Ọgwụ na usoro isiokwu a na-emepụta na-adịghị adịte mmetụta, na mere ike ga-ndinọ na Nchikota ọgwụ, oké ụdị II-arịa ọrịa shuga.

"Novonorm"

Oral hypoglycemic ọgwụ nke dị na pharmacies dị ka mbadamba. The ọgwụ na-kenyere mgbe nri ọgwụ na mmega ahụ na-enye ezigbo ihe. Ọrịa na Type II-arịa ọrịa shuga na-iri "Novanorm" na Nchikota na ndị ọzọ antidiabetic elekọta mmadụ. N'ihi ya, ọrịa na-enwe ike ọzọ anya nyochaa larịị nke glucose.

Mbadamba "Novanorm" expedient eji na Nchikota na nri. Ọgwụ e ji ọnụ na tupu a nri ugboro atọ n'ụbọchị. Na obere okwu, na onunu ogwu nwere ike mụbara. Ọrịa na-ewekarị snacking ma ọ bụ awụgharị nri, kwesịrị ịga hụ dọkịta banyere "Novanorm" correctness nke na-ewere ọgwụ.

Dị ka ekwuola, hypoglycemic mmadụ maka ọrịa shuga na-bụghị mgbe niile kara aka. Ụfọdụ jikwaa ịchịkwa larịị nke glucose dị n'ọbara naanị site nri. Mbadamba "Novanorm" nwere ike ji mee ihe mgbe nwa oge ejitelighị glycemia. Mmetụta nke ọgwụ ndị obere na-adịru nwa oge. Onye ọrịa nwere ike ọgbụgbọ na abdominal mgbu. Erughị ala ngwa ngwa na-agafe. Kagbuo ọgwụ naanị na ikpe nke onye ekweghị ibe nọrọ. Mbadamba na-contraindicated "Novanorm" ụmụ, ndị inyom n'oge ime na lactation, na ọrịa na oké hepatic impairment.

biguanides

Nhazi ọkwa nke antidiabetic ọgwụ ọjọọ ga-agụnye ego metụtara ndị biguanide otu. Ọgwụ a na n'isiokwu na-adịghị maka na mmetuta nke insulin secretion. N'agbanyeghị nke a, biguanides akpọ ọrụ dị mkpa na ọgwụgwọ nke ụdị II-arịa ọrịa shuga, dị ka ụba elu glucose itinye n'ọrụ ahụ arọ. Products dannog eschestva imeju budata belata. Biguanides nwere ike budata belata ọbara glucose etoju. N'ọnọdụ ụfọdụ, ọ bụ na o kwere omume iji nweta niile kwesịrị egosi. Isi contraindications na ojiji nke ndị dị otú ahụ ọgwụ ọjọọ eme ihe bụ predkomatoznoe ala na ọrịa na-arịa ọrịa shuga. Anya ndinọ hypoglycemic mmadụ 3rd ọgbọ ọrịa na-enwe ọchịchọ na-aba n'anya, nakwa dị ka isi imeju ọrụ.

"Metformin"

Oral hypoglycemic ọgwụ ọjọọ nke na biguanide otu. The ọgwụ dị na pharmacies dị ka mbadamba. Isi nọ n'ọrụ mgwa akwụsị absorption nke glucose ke gootu, nakwa dị ka nnukwu abawanye glucose itinye n'ọrụ na elu arọ. Hypoglycemic Jeremaya mere mkpụrụ ọgwụ "Metformin" ghara ime ka. The ọgwụ na-ndinọ ka ọrịa na Type II-arịa ọrịa shuga na-enweghị ọchịchọ ketoacidosis. Mbadamba nwekwara ike ga-ndinọ na Nchikota na insulin ọrịa na-ata ahụhụ si na ibu oké ibu.

Dabere na larịị nke glucose dị n'ọbara, dọkịta n'otu n'otu ka na onunu ogwu nke ọgwụ. Ọgwụgwọ nwere ike na-amalite a n'ikuku nke otu mbadamba kwa ụbọchị (500 mg). The nwayọọ nwayọọ na-abawanye na dose nwere ike na-amalite na mgbe izu abụọ nke na-aga n'ihu na ọgwụgwọ. The kacha kwa ụbọchị dose ekwesịghị gafere 6 mbadamba. Ọrịa okenye karịrị afọ 70 na-ekwesịghị-ewe ihe karịrị 2 mbadamba kwa ụbọchị.

Hypoglycemic mbadamba formulations na-contraindicated n'ihi na ndị mmadụ na isi akụrụ. Ọ bụrụ na e a ọrịa nke pụrụ iduga belata akụrụ ọrụ, mkpụrụ ọgwụ "Metformin 'na nwa oge kagbuo. Ị gaghị ewere ha na a oge nke ukpụhọde mgbe ịwa ahụ. Contraindication bụ oké njọ nnukwu mmanya nsi.

Alpha-glucosidase inhibitors

Otu a ọgwụ ọjọọ nwere ike na-egbochi mmepụta nke kpọmkwem nsia enzyme (Alfa-glucosidase). Site na nke a usoro nke formulations budata belata absorption isi carbohydrates dị ka starch, sucrose, na maltose. Na ikpe ziri ezi n'ikuku nke oge a antidiabetic ọgwụ ọjọọ na otu a na-enweghị nnọọ mmetụta. Kpamkpam na-anọghị erughị ala na eriri afọ na afo mgbu.

Alpha-glucosidase inhibitors kwesịrị iwere na nke mbụ njuputaonu nri. Gbarie tinyere nri, na nkà mmụta ọgwụ mmiri inye ezi hypoglycemic mmetụta. Ọgwụ na usoro isiokwu a nwere ike iwere ya na n'aka a sulfonylurea ma ọ bụ insulin. Ihe ize ndụ nke hypoglycemia abawanye.

"Miglitol"

Hypoglycemic gị n'ụlọnga nke na ìgwè nke Alfa-glyueozidaz inhibitors. Kenyere ka ọrịa na-agafeghị oke ụdị II-arịa ọrịa shuga na ihe omume ahụ ezigbo mmega ahụ na nri adịghị egboro a kwesịrị ekwesị n'ihi. Mbadamba "miglitol" bụ kasị dị irè mgbe eji na ihe efu afo. Na obere okwu, n'ihu ikpo na ndị ọzọ ọnụ na hypoglycemic mmadụ. Nhazi ọkwa pụtara ịchịkwa larịị nke glucose dị n'ọbara a n'ihu n'elu.

Isi mmiri "miglitol" ọgwụ ọjọọ kpamkpam etinye obi gị dum n'ime anụ ahụ na proviso anata ala doses (1-2 mbadamba). Na a dose nke 50 g nke absorption 90%. The n'ọrụ mgwa na-anyụpụ site na akụrụ na-agbanweghi agbanwe. Antidiabetic ọgwụ adịghị kenyere maka ụmụaka nakwa dị ka ime, lactating inyom. Contraindication bụ ala ala bowel ọrịa, nakwa dị ka nnukwu hainia. Mmetụta mgbe na-ewere ọgwụ "miglitol" bụ obere. E nwere mgbe nke nfụkasị Jeremaya dị ka ihe ọkụ ọkụ na itching.

Jikọtara hypoglycemic mmadụ

N'ọnọdụ ka ukwuu, ọgwụgwọ nke ụdị II-arịa ọrịa shuga na-amalite na monotherapy. Ọzọ ọgwụ ọjọọ nwere ike na-kenyere naanị mgbe ọgwụgwọ adịghị enye ndị kwesịrị ekwesị N'ihi. Nsogbu bụ na otu ọgwụ adịghị mgbe ekpuchi ọtụtụ nsogbu ndị na-arịa ọrịa shuga. Dochie multiple ọgwụ ọjọọ nke dị iche iche ọmụmụ nwere ike ikpokọta na otu hypoglycemic n'ụlọnga. Ndị dị otú ahụ ọgwụ ga-abụ ihe nchebe. Mgbe niile, budata belata ihe ize ndụ nke mmetụta. Ndị kasị dị irè, dị ka dọkịta, bụ Nchikota metformin na thiazolidinediones na sulfonylureas na metformin.

Jikọtara ọgwụ ọjọọ e mere maka ọgwụgwọ nke ụdị II-arịa ọrịa shuga na-enwe ike ịkwụsị progression nke hyperinsulinemia. N'ihi nke a, ọrịa na-eche nnọọ mma ma na-enwe ike ida a obere ibu ibu. N'ọnọdụ ka ukwuu, ọ dị mkpa ka ntughari ka insulin ọgwụ kpamkpam tutu amama.

Otu n'ime ndị kasị ewu ewu na jikọrọ antidiabetic ọgwụ ọjọọ bụ "Glibomet". Hapụ agwọ ọrịa na mbadamba ụdị. Ha na-ahọpụta mgbe gara aga ọgwụgwọ na-egosighị ezi ihe. Unu na-eji a ọgwụ na-emeso-arịa ọrịa shuga mbụ ụdị. Mbadamba na-contraindicated ka ndị mmadụ na isi imeju ọrụ ma ọ bụ gbasara akụrụ insufficiency. Ụmụaka na ndị inyom n'oge ime na lactation ọgwụ na-adịghị gosiri.

"Glibomet" mkpụrụ ọgwụ nwere ọtụtụ mmetụta. Ha nwere ike ime ka afọ ọsịsa, ọgbụgbọ, dizziness. Obere yiri ka ịzụlite nfụkasị Jeremaya dị ka akpụkpọ ọkụ ọkụ na itching. Iji nke ọgwụ na-atụ aro nditịm na ndenye ọgwụ.